The Latest Breaking News from Dupixent

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

Regeneron stock rose Friday after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.

Regeneron and Sanofi said Monday their blockbuster drug, Dupixent, significantly improved symptoms COPD symptoms.

Celldex could rival a key Regeneron drug, an analyst said Monday as CLDX stock rocketed on the results of multiple studies.

The U.S.

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

AbbVie could soon pressure Regeneron in eczema treatment, an analyst said Friday as Regeneron stock hit a ceiling at its 200-day line.

Sanofi stock rose Thursday on strong revenue growth for the company's allergic conditions treatment, Dupixent.

As surging inflation and energy prices foster recessionary fears, it could be wise to bet on non-cyclical stocks because they tend to outperform the broader market when economic growth slows. Given the inelastic demand for their companies’ products, we think the shares of United Parcel Service (UPS), British American Tobacco…